These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The biosimilar Ustekinumab has been developed and manufactured by the company
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Puri is an accomplished leader and financial sector veteran with over four decades of experience
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Subscribe To Our Newsletter & Stay Updated
